Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.13, for a total value of $1,500,780.00. Following the sale, the director directly owned 351,875 shares of the company’s stock, valued at $88,014,493.75. This represents a 1.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 0.8%

JAZZ stock opened at $245.57 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The company’s 50-day simple moving average is $248.38 and its 200 day simple moving average is $220.39. Jazz Pharmaceuticals PLC has a 52 week low of $123.88 and a 52 week high of $266.38. The company has a market capitalization of $15.94 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 0.22 and a beta of 0.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the firm earned ($8.25) EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on JAZZ. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Needham & Company LLC lifted their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Finally, Royal Bank Of Canada set a $299.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $285.44.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH boosted its stake in Jazz Pharmaceuticals by 68.2% during the fourth quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock worth $101,801,000 after acquiring an additional 242,892 shares in the last quarter. Castleark Management LLC bought a new stake in Jazz Pharmaceuticals in the first quarter valued at $9,214,000. SEB Asset Management AB acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at about $8,765,000. Swedbank AB raised its holdings in shares of Jazz Pharmaceuticals by 2.7% during the fourth quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock valued at $187,506,000 after purchasing an additional 28,882 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.